Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,317 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,003 Underlying: Common Stock · 16,317 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 730 | $32.50 | $23,725.00 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.42 to $32.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 5,581 | $31.98 | $178,480.38 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.40 to $32.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 10,006 | $30.47 | $304,882.82 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.05 to $30.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 16,317 | $12.21 | $199,230.57 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 4,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-011062 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,709,998 F7 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:57 UTC |
Kim Lorence H.Chief Financial Officer
|
SaleCommon Stock | 1,134 | $27.39 | $31,060.26 |
DisclosureSEC source: 0001127602-20-011272 · form4.xml · nonDerivative · entry 4 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,242,510 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.25 to $27.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:57 UTC |
Kim Lorence H.Chief Financial Officer
|
SaleCommon Stock | 9,370 | $26.74 | $250,553.80 |
DisclosureSEC source: 0001127602-20-011272 · form4.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243,644 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.24 to $27.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:57 UTC |
Kim Lorence H.Chief Financial Officer
|
SaleCommon Stock | 6,704 | $25.85 | $173,298.40 |
DisclosureSEC source: 0001127602-20-011272 · form4.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253,014 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $26.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:57 UTC |
Kim Lorence H.Chief Financial Officer
|
SaleCommon Stock | 2,792 | $24.68 | $68,906.56 |
DisclosureSEC source: 0001127602-20-011272 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259,718 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.19 to $25.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 203 | $23.06 | $4,681.18 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,046,540 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.96 to $23.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,100 | $22.43 | $24,673.00 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,046,743 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.95 to $22.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,387 | $21.29 | $29,529.23 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,843 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.76 to $21.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,300 | $20.29 | $46,667.00 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049,230 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.67 to $20.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 10,000 | $23.00 | $230,000.00 |
DisclosureSEC source: 0001127602-20-010793 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,425 | $22.93 | $32,675.25 |
DisclosureSEC source: 0001127602-20-011062 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 695,914 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.69 to $23.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,165 | $22.03 | $47,694.95 |
DisclosureSEC source: 0001127602-20-011062 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 697,339 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.59 to $22.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,909 | $20.99 | $82,049.91 |
DisclosureSEC source: 0001127602-20-011062 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 699,504 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.58 to $21.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,547 | $20.14 | $71,436.58 |
DisclosureSEC source: 0001127602-20-011062 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 703,413 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.57 to $20.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 13, 2020 Filed Jul 16, 2020 00:03 UTC Amendment |
Hoge StephenPresident
|
SaleCommon Stock | 1,110 | $22.43 | $24,897.30 |
DisclosureSEC source: 0001127602-20-021585 · form4a.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,046,733 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018. F2 · shares: The Form 4 filed on March 16, 2020 by the reporting person inadvertently understated the number of shares sold by the reporting person by 10 shares. Such 10 shares were also inadvertently included in Column 5 of Forms 4 filed by the reporting person after such date. This Form 4 corrects such error by increasing the number of shares sold in this transaction, and decreasing the total amount of securities beneficially owned by the reporting person immediately after this transaction, by such 10 shares. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.95 to $22.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 100 | $24.16 | $2,416.00 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,051,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,874 | $23.55 | $44,132.70 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,051,630 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.12 to $23.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:21 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 3,026 | $22.56 | $68,266.56 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,053,504 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.07 to $23.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:31 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,117 | $25.71 | $105,848.07 |
DisclosureSEC source: 0001127602-20-010262 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,224,912 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:31 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 8,234 | $25.71 | $211,696.14 |
DisclosureSEC source: 0001127602-20-010262 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,937,269 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:31 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,117 | $25.71 | $105,848.07 |
DisclosureSEC source: 0001127602-20-010262 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,714,674 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:37 UTC |
LEE JENNIFER LINGChief Accounting Officer
|
SaleCommon Stock | 361 | $27.33 | $9,865.62 |
DisclosureSEC source: 0001127602-20-010280 · form4.xml · nonDerivative · entry 1 LEE JENNIFER LING · CIK 0001675118 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 104 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,320 Underlying: Common Stock · 104 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 104 | $30.00 | $3,120.00 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 104 | $12.21 | $1,269.84 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 10,000 | $27.98 | $279,800.00 |
DisclosureSEC source: 0001127602-20-010107 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:15 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 6,901 | $29.26 | $201,923.26 |
DisclosureSEC source: 0001127602-20-010096 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 706,960 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.78 to $29.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:15 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,145 | $28.27 | $117,179.15 |
DisclosureSEC source: 0001127602-20-010096 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 713,861 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.71 to $28.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:13 UTC |
Kim Lorence H.Chief Financial Officer
|
SaleCommon Stock | 20,000 | $27.71 | $554,200.00 |
DisclosureSEC source: 0001127602-20-009810 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,510 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.40 to $28.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:53 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,857 | $27.09 | $104,486.13 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 7 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,229,029 F7 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:53 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 7,713 | $27.09 | $208,945.17 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 6 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,945,503 F7 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F8 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:53 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,857 | $27.09 | $104,486.13 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,718,791 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,001 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,424 Underlying: Common Stock · 3,001 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 3,001 | $30.12 | $90,390.12 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 3,001 | $12.21 | $36,642.21 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:05 UTC |
Andres JuanSee remarks
|
GrantRestricted Stock Units · Derivative | 28,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Underlying: Common Stock · 28,924 shares Expires not disclosed F8 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:05 UTC |
Andres JuanSee remarks
|
GrantStock Option (Right to Buy) · Derivative | 161,120 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,120 Underlying: Common Stock · 161,120 shares Expires 2030-02-28 F7 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:39 UTC |
Hoge StephenPresident
|
GrantRestricted Stock Units · Derivative | 38,565 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009039 · form4.xml · derivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,565 Underlying: Common Stock · 38,565 shares Expires not disclosed F2 · derivative.exercise_date: 50% of this restricted stock unit will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F2 · derivative.expiration_date: 50% of this restricted stock unit will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:39 UTC |
Hoge StephenPresident
|
GrantStock Option (Right to Buy) · Derivative | 214,826 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009039 · form4.xml · derivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,826 Underlying: Common Stock · 214,826 shares Expires 2030-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:35 UTC |
Zaks Tal ZviChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 28,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009028 · form4.xml · derivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Underlying: Common Stock · 28,924 shares Expires not disclosed F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:35 UTC |
Zaks Tal ZviChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 161,120 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009028 · form4.xml · derivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,120 Underlying: Common Stock · 161,120 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:35 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 10,000 | $23.38 | $233,800.00 |
DisclosureSEC source: 0001127602-20-009028 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:58 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 157,539 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009092 · form4.xml · derivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,539 Underlying: Common Stock · 157,539 shares Expires 2030-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:53 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 644,480 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · derivative · entry 8 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,480 Underlying: Common Stock · 644,480 shares Expires 2030-02-28 F10 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:53 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,450 | $24.36 | $35,322.00 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 718,006 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.15 to $24.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.